Cutaneous myeloid sarcoma following neoadjuvant chemotherapy for breast carcinoma
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20222157Keywords:
MS, Breast cancer, Systemic chemotherapyAbstract
Myeloid sarcoma (MS) is a neoplasm composed of myeloid blasts occurring outside the bone marrow, most often found simultaneously, or after a diagnosis of acute myeloid leukemia. Very rarely, de novo MS has been diagnosed in patients with a prior history of non-hematolymphoid neoplasms treated with systemic chemotherapy. We report a case of a MS in a 43-year-old woman, 6 months after the diagnosis of a HER2+ breast carcinoma, treated with neoadjuvant chemotherapy. Chemotherapy drugs could have played a pathogenic role in the development of MS in this patient. The exceeding rarity of such cases does make further and broader studies fundamental, in order to clarify if and which chemotherapy drugs may be the cause of MS.
Metrics
References
Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients. Am J Surg Pathol. 2016;40(11):1473-83.
Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options. Ther Adv Hematol. 2011;2(5):309-16.
Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340-50.
Jadhav T, Baveja P, Sen A. Myeloid sarcoma: an uncommon presentation of myeloid neoplasms; a case series of 4 rare cases reported in a tertiary care institute. Autops Case Rep. 2021;11:e2021339.
Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma. 2006;47(12):2527-41.
Downloads
Published
How to Cite
Issue
Section
